Division of Otolaryngology-Head and Neck Surgery, Children's National Medical Center, Washington, DC 20010, USA.
JAMA Otolaryngol Head Neck Surg. 2013 Mar;139(3):223-7. doi: 10.1001/jamaoto.2013.1703.
The widespread use of the 7-valent pneumococcal conjugate vaccine (PVC7), developed to combat invasive Streptococcus pneumoniae infections, has the potential to influence the prevalence and antibiotic resistance patterns of pathogens associated with orbital complications from acute sinusitis. Given the significant morbidity that may result from inadequate treatment of orbital infections related to acute sinusitis, determining the impact of PCV7 on the bacteriology and drug resistance of the pathogens associated with these infections may provide critical information needed to accurately guide optimal clinical management.
To determine if the characteristics of orbital complications from acute sinusitis in children have changed in the post-PCV7 era.
Review of clinical data.
Tertiary care children's hospital.
Patients with a diagnosis of orbital cellulitis and/or subperiosteal abscess from January 1, 1996, to December 31, 2009. Patients with immune deficiency or orbital trauma were excluded. Patients were divided into pre-PCV7 (before 2003 [n = 128]) and post-PCV7 (2003 and after [n = 145]) groups. Statistical analyses were used to compare the 2 groups.
Differences in patient demographics, signs and symptoms, laboratory study results, computed tomography scan findings, and microbiological analyses between the pre-PCV7 and post-PCV7 groups.
A total of 273 children met the inclusion criteria. The post-PCV7 group was older (71.4 months vs 88.8 months [P = .007]) than the pre-PCV7 group. A significant decrease in S pneumoniae and Streptococcus viridans -positive sinus or blood cultures were observed (22.4% vs 0% [P < .001] and 12.24% vs 0% [P = .005], respectively). An increase in Staphylococcus aureus was seen in the post-PCV7 group (20.4% vs 42.37% [P = .02]). Methicillin-resistant S aureus (MRSA) was isolated only in the post-PCV7 group (P = .002). The pre-PCV7 group had a significantly longer hospital stay than the post-PCV7 group (7.15 days vs 5.47 days [P = .004]).
Although universal PCV7 vaccination has eliminated S pneumoniae as an etiologic pathogen in acute sinusitis complications in this series, there has been a parallel and significant increase in S aureus, including an increase in the prevalence of MRSA associated with orbital infections related to acute sinusitis.
为了对抗侵袭性肺炎链球菌感染而开发的 7 价肺炎球菌结合疫苗(PCV7)广泛应用,可能会影响与急性鼻窦炎相关的眶并发症的病原体的流行和抗生素耐药模式。鉴于急性鼻窦炎相关眶感染治疗不充分可能导致严重的发病率,确定 PCV7 对与这些感染相关的病原体的细菌学和药物耐药性的影响,可能提供准确指导最佳临床管理所需的关键信息。
确定儿童急性鼻窦炎眶并发症的特征是否在 PCV7 后时代发生了变化。
临床数据回顾。
三级儿童医院。
1996 年 1 月 1 日至 2009 年 12 月 31 日期间诊断为眶蜂窝织炎和/或骨膜下脓肿的患者。排除免疫缺陷或眶外伤患者。患者分为 PCV7 前(2003 年之前[n=128])和 PCV7 后(2003 年及以后[n=145])组。使用统计分析比较两组。
PCV7 前组和 PCV7 后组患者的人口统计学特征、体征和症状、实验室研究结果、计算机断层扫描结果和微生物分析差异。
共有 273 名符合纳入标准的儿童。PCV7 后组年龄较大(71.4 个月比 88.8 个月[P=0.007])。S 肺炎链球菌和草绿色链球菌阳性窦或血培养的显著减少(22.4%比 0%[P<0.001]和 12.24%比 0%[P=0.005])。PCV7 后组金黄色葡萄球菌增加(20.4%比 42.37%[P=0.02])。仅在 PCV7 后组分离出耐甲氧西林金黄色葡萄球菌(MRSA)(P=0.002)。PCV7 前组的住院时间明显长于 PCV7 后组(7.15 天比 5.47 天[P=0.004])。
尽管普遍使用 PCV7 疫苗已消除了本系列急性鼻窦炎并发症中 S 肺炎链球菌作为病因,但金黄色葡萄球菌的平行且显著增加,包括与急性鼻窦炎相关的眶感染相关的 MRSA 患病率增加。